Compare Gilead Sciences, Inc. (GILD) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Silver Trust — how do they compare? Gilead Sciences, Inc. trades at $135.95 (market cap $168.35B), while iShares Silver Trust trades at $59.64. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while iShares Silver Trust pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| GILD | SLV | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $105.57 |
52-Week Low | $110.56 | $33.89 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
SLV trades at $59.45, showing minimal daily movement with a 0.07% gain. The technical outlook is bullish with strong moving average support, though RSI levels suggest potential overbought conditions near-term. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, with the metal recovering from earlier 2026 declines.
Silver's investment case remains compelling due to structural supply constraints and growing industrial demand, particularly from technology sectors. Key risks include Federal Reserve policy uncertainty and dollar strength, while technical resistance near $60 presents immediate price challenges. The metal's volatility requires careful position sizing despite positive long-term fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
